{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:19:53Z","timestamp":1793737193667,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"DOI":"10.1038\/s41431-026-02131-9","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:59:31Z","timestamp":1779965971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From evidence to implementation: key priorities for pharmacogenomics-guided treatment and prevention from a European expert workshop"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1261-2787","authenticated-orcid":false,"given":"Loes Lindiwe","family":"Kreeftenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-0597","authenticated-orcid":false,"given":"Lidewij","family":"Henneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6038-6289","authenticated-orcid":false,"given":"Tessel","family":"Rigter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica Valz","family":"Gris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"LLerena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8706-3159","authenticated-orcid":false,"given":"Maureen","family":"Rutten-van M\u00f6lken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid Moura","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7640-1239","authenticated-orcid":false,"given":"Videha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-5552","authenticated-orcid":false,"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-5544","authenticated-orcid":false,"given":"Martina C.","family":"Cornel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2201-2320","authenticated-orcid":false,"given":"Carla G.","family":"van El","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2131_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(19)31276-0","volume":"394","author":"DM Roden","year":"2019","unstructured":"Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, et al. Pharmacogenomics. Lancet. 2019;394:521.","journal-title":"Lancet"},{"key":"2131_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.29252\/beat-070401","volume":"7","author":"MB Ayalew","year":"2019","unstructured":"Ayalew MB, Tegegn HG, Abdela O. Drug related hospital admissions; a systematic review of the recent literatures. Bull Emerg Trauma. 2019;7:339\u201346.","journal-title":"Bull Emerg Trauma"},{"key":"2131_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56855-z","volume":"14","author":"J Komagamine","year":"2024","unstructured":"Komagamine J. Prevalence of urgent hospitalizations caused by adverse drug reactions: a cross-sectional study. Sci Rep. 2024;14:6058.","journal-title":"Sci Rep"},{"key":"2131_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41576-022-00572-8","volume":"24","author":"M Pirmohamed","year":"2023","unstructured":"Pirmohamed M. nature reviews genetics Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023;24:350\u201362.","journal-title":"Nat Rev Genet"},{"key":"2131_CR5","doi-asserted-by":"publisher","first-page":"e055551","DOI":"10.1136\/bmjopen-2021-055551","volume":"12","author":"R Osanlou","year":"2022","unstructured":"Osanlou R, Walker L, Hughes DA, Burnside G, Pirmohamed M. Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. BMJ Open. 2022;12:e055551.","journal-title":"BMJ Open"},{"key":"2131_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cts.12404","volume":"9","author":"MJ Arwood","year":"2016","unstructured":"Arwood MJ, Chumnumwat S, Cavallari LH, Nutescu EA, Duarte JD. Implementing pharmacogenomics at your institution: establishment and overcoming implementation challenges. Clin Transl Sci. 2016;9:233.","journal-title":"Clin Transl Sci"},{"key":"2131_CR7","first-page":"197","volume":"18","author":"NL Wittwer","year":"2025","unstructured":"Wittwer NL, Meier CR, Huber CA, Moser JD, Meyer Zu Schwabedissen HE, Allemann SS, et al. The prevalence of potential drug-drug-gene interactions: a descriptive study using Swiss claims data. Pharmgenomics Pers Med. 2025;18:197\u2013208.","journal-title":"Pharmgenomics Pers Med"},{"key":"2131_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/jpm15060245","volume":"15","author":"X D\u00edaz-Villamar\u00edn","year":"2025","unstructured":"D\u00edaz-Villamar\u00edn X, Mart\u00ednez-P\u00e9rez M, Nieto-S\u00e1nchez MT, Fern\u00e1ndez-Var\u00f3n E, Torres-Garc\u00eda A, Blancas I, et al. Clinical pharmacogenetics: results after implementation of preemptive tests in daily routine. J Personal Med. 2025;15:245.","journal-title":"J Personal Med"},{"key":"2131_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-019-0229-z","volume":"13","author":"K Krebs","year":"2019","unstructured":"Krebs K, Milani L. Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Hum Genom. 2019;13:39.","journal-title":"Hum Genom"},{"key":"2131_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/14622416.2025.2504862","volume":"26","author":"AHA Roelofsen","year":"2025","unstructured":"Roelofsen AHA, Kreeftenberg LL, van El CG, Henneman L, Rigter T, Sie D, et al. Barriers and facilitators for implementing a pharmacogenetic passport: lessons learned from reusing sequencing data. Pharmacogenomics. 2025;26:143\u201356.","journal-title":"Pharmacogenomics"},{"key":"2131_CR11","doi-asserted-by":"publisher","first-page":"e49230","DOI":"10.2196\/49230","volume":"26","author":"V Sharma","year":"2024","unstructured":"Sharma V, McDermott J, Keen J, Foster S, Whelan P, Newman W. Pharmacogenetics clinical decision support systems for primary care in England: co-design study. J Med Internet Res. 2024;26:e49230.","journal-title":"J Med Internet Res"},{"key":"2131_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/CEJ.0000000000000873","volume":"33","author":"R Pastorino","year":"2024","unstructured":"Pastorino R, Pezzullo AM, Osti T, Adany R, Borry P, Barnhoorn F, et al. The PROPHET project paves the way for personalized prevention in the future healthcare. Eur J Cancer Prev. 2024;33:387\u20139.","journal-title":"Eur J Cancer Prev"},{"key":"2131_CR13","unstructured":"LL Kreeftenberg AR, MC Cornel, T Rigter, CG van El, C T4.3.PROPHET-Pharmacogenomics-Expert-workshop_Amsterdam-UMC PROPHET; 2025. Available from: https:\/\/prophetproject.eu\/wp-content\/uploads\/2025\/05\/T4.3.PROPHET-Pharmacogenomics-Expert-workshop_Amsterdam-UMC.pdf [Accessed in July 2025]."},{"key":"2131_CR14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40273-021-01010-z","volume":"39","author":"H Vellekoop","year":"2021","unstructured":"Vellekoop H, Huygens S, Versteegh M, Szilberhorn L, Zelei T, Nagy B, et al. Guidance for the harmonisation and improvement of economic evaluations of personalised medicine. PharmacoEconomics. 2021;39:771\u201388.","journal-title":"PharmacoEconomics"},{"key":"2131_CR15","unstructured":"PharmGKB. DPWG: Dutch Pharmacogenetics Working Group 2024. 2025. Availble from: https:\/\/www.pharmgkb.org\/page\/dpwg. [Accessed in November 2025]."},{"key":"2131_CR16","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/cpt.2754","volume":"112","author":"SA Morris","year":"2022","unstructured":"Morris SA, Alsaidi AT, Verbyla A, Cruz A, Macfarlane C, Bauer J, et al. Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review. Clin Pharm Ther. 2022;112:1318\u201328.","journal-title":"Clin Pharm Ther"},{"key":"2131_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev-pharmtox-061724-080935","volume":"65","author":"R Mosch","year":"2025","unstructured":"Mosch R, van der Lee M, Guchelaar HJ, Swen JJ. Pharmacogenetic panel testing: a review of current practice and potential for clinical implementation. Annu Rev Pharmacol Toxicol. 2025;65:91\u2013109.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2131_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","volume":"401","author":"JJ Swen","year":"2023","unstructured":"Swen JJ, van der Wouden CH, Manson LEN, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401:347\u201356.","journal-title":"Lancet"},{"key":"2131_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105009","volume":"101","author":"M Skokou","year":"2024","unstructured":"Skokou M, Karamperis K, Koufaki MI, Tsermpini EE, Pandi MT, Siamoglou S, et al. Clinical implementation of preemptive pharmacogenomics in psychiatry. EBioMedicine. 2024;101:105009.","journal-title":"EBioMedicine"},{"key":"2131_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-023-00495-3","volume":"17","author":"MI Koufaki","year":"2023","unstructured":"Koufaki MI, Fragoulakis V, D\u00edaz-Villamar\u00edn X, Karamperis K, Vozikis A, Swen JJ, et al. Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study. Hum Genom. 2023;17:51.","journal-title":"Hum Genom"},{"key":"2131_CR21","doi-asserted-by":"crossref","unstructured":"Haga SB, Burke W. Using pharmacogenetics to improve drug safety and efficacy. JAMA. 2004;291:2869\u201371.","DOI":"10.1001\/jama.291.23.2869"},{"key":"2131_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-025-00780-3","volume":"19","author":"NAH Hatem","year":"2025","unstructured":"Hatem NAH, Badullah W, Yousuf SA, Ibrahim MIM, Haidar WA, Zawiah M. Pharmacists\u2019 perspectives on integrating pharmacogenetics in clinical practice. Hum Genomics. 2025;19:71.","journal-title":"Hum Genomics"},{"key":"2131_CR23","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.sapharm.2023.07.012","volume":"19","author":"S Omran","year":"2023","unstructured":"Omran S, Leong SL, Blebil A, Mohan D, Teoh SL. Effectiveness of pharmacogenomics educational interventions on healthcare professionals and health professions students: a systematic review. Res Soc Adm Pharm. 2023;19:1399\u2013411.","journal-title":"Res Soc Adm Pharm"},{"key":"2131_CR24","doi-asserted-by":"publisher","first-page":"1199462","DOI":"10.3389\/fphar.2023.1199462","volume":"14","author":"A Bignucolo","year":"2023","unstructured":"Bignucolo A, De Mattia E, Roncato R, Peruzzi E, Scarabel L, D\u2019Andrea M, et al. Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: lessons learned on the path to implementation. Front Pharmacol. 2023;14:1199462.","journal-title":"Front Pharmacol"},{"key":"2131_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2217\/pgs-2021-0131","volume":"23","author":"S Qureshi","year":"2022","unstructured":"Qureshi S, Latif A, Condon L, Akyea RK, Kai J, Qureshi N. Understanding the barriers and enablers of pharmacogenomic testing in primary care: a qualitative systematic review with meta-aggregation synthesis. Pharmacogenomics. 2022;23:135\u201354.","journal-title":"Pharmacogenomics"},{"key":"2131_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58465-3","volume":"16","author":"L Milani","year":"2025","unstructured":"Milani L, Alver M, Laur S, Reisberg S, Haller T, Aasmets O, et al. The Estonian Biobank\u2019s journey from biobanking to personalized medicine. Nat. Commun. 2025;16:3270.","journal-title":"Nat. Commun"},{"key":"2131_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-24925-0","volume":"25","author":"LL Kreeftenberg","year":"2025","unstructured":"Kreeftenberg LL, Henneman L, Louati C, Zeisl Y, de Luca EC, Quaggia D, et al. Personalised prevention: what patients and citizen advocates want for better engagement \u2013 a qualitative study. BMC Public Health. 2025;25:3777.","journal-title":"BMC Public Health"},{"key":"2131_CR28","unstructured":"EPF. European Patients Forum. The added value of patient organisations. 2017. Available from: https:\/\/www.eu-patient.eu\/globalassets\/library\/publications\/epf_added_value_report_final.pdf [Accessed in October 2025]."},{"key":"2131_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1515\/dmpt-2024-0042","volume":"39","author":"M Apellaniz-Ruiz","year":"2024","unstructured":"Apellaniz-Ruiz M, Barrachina J, Castro-Sanchez P, Comes-Raga A, Garc\u00eda-Gonz\u00e1lez X, Gil-Rodriguez A, et al. Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives. Drug Metab Personalized Ther. 2024;39:183\u201399.","journal-title":"Drug Metab Personalized Ther"},{"key":"2131_CR30","doi-asserted-by":"publisher","first-page":"e101163","DOI":"10.1136\/bmjhci-2024-101163","volume":"32","author":"V Sharma","year":"2025","unstructured":"Sharma V, McDermott J, Keen J, McIntyre B, Watson S, Newman W. Designing an interoperable solution to support pharmacogenomic-guided prescribing in primary care: an implementer report. BMJ Health Care Inf. 2025;32:e101163.","journal-title":"BMJ Health Care Inf"},{"key":"2131_CR31","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.2146\/ajhp160030","volume":"73","author":"JK Hicks","year":"2016","unstructured":"Hicks JK, Dunnenberger HM, Gumpper KF, Haidar CE, Hoffman JM. Integrating pharmacogenomics into electronic health records with clinical decision support. Am J Health Syst Pharm. 2016;73:1967\u201376.","journal-title":"Am J Health Syst Pharm"},{"key":"2131_CR32","doi-asserted-by":"crossref","unstructured":"Sharma V, McDermott J, Keen J, Koikkalainen H, McNicoll I, Newman W. Enabling precision medicine through open standards in pharmacogenetics: data model development and Delphi study (Preprint). JMIR Preprints. 2024.","DOI":"10.2196\/preprints.65689"},{"key":"2131_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fsoc.2023.1122488","volume":"8","author":"NA Walton","year":"2023","unstructured":"Walton NA, Christensen GB. Paving a pathway for large-scale utilization of genomics in precision medicine and population health. Front Socio. 2023;8:1122488.","journal-title":"Front Socio"},{"key":"2131_CR34","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2217\/pgs-2020-0066","volume":"21","author":"D Roosan","year":"2020","unstructured":"Roosan D, Hwang A, Law AV, Chok J, Roosan MR. The inclusion of health data standards in the implementation of pharmacogenomics systems: a scoping review. Pharmacogenomics. 2020;21:1191\u2013202.","journal-title":"Pharmacogenomics"},{"key":"2131_CR35","doi-asserted-by":"publisher","unstructured":"Benson T, Grieve G. Principles of health interoperability: SNOMED CT, HL7 and FHIR. 2016. https:\/\/doi.org\/10.1007\/978-3-319-30370-3.","DOI":"10.1007\/978-3-319-30370-3"},{"key":"2131_CR36","doi-asserted-by":"publisher","first-page":"507184","DOI":"10.3389\/fgene.2020.00010","volume":"11","author":"T Rigter","year":"2020","unstructured":"Rigter T, Jansen ME, Groot JMD, Janssen SWJ, Rodenburg W, Cornel MC. Implementation of pharmacogenetics in primary care: a multi-stakeholder perspective. Front Genet. 2020;11:507184.","journal-title":"Front Genet"},{"key":"2131_CR37","doi-asserted-by":"publisher","first-page":"945352","DOI":"10.3389\/fmed.2022.945352","volume":"9","author":"JH McDermott","year":"2022","unstructured":"McDermott JH, Wright S, Sharma V, Newman WG, Payne K, Wilson P. Characterizing pharmacogenetic programs using the consolidated framework for implementation research: a structured scoping review. Front Med. 2022;9:945352.","journal-title":"Front Med"},{"key":"2131_CR38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/tpj.2014.86","volume":"15","author":"F Ehmann","year":"2015","unstructured":"Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenom J. 2015;15:201\u201310.","journal-title":"Pharmacogenom J"},{"key":"2131_CR39","doi-asserted-by":"crossref","unstructured":"Gratton J, Arlett P, Ehmann F, Prieto-Alhambra D, Verpillat P, Cormier E, et al. Advancing pharmacogenomics in medicines regulation and clinical practice: a call for collaborative action. Nat Rev Drug Discov. 2025;25:79\u201380.","DOI":"10.1038\/d41573-025-00178-9"},{"key":"2131_CR40","unstructured":"Regulation (EU) 2021\/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011\/24\/EU (Text with EEA relevance). 2021. Available from: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=uriserv:OJ.L_.2021.458.01.0001.01.ENG. [Accessed in October 2025]."},{"key":"2131_CR41","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/eurpub\/ckaf047","volume":"35","author":"A Valz Gris","year":"2025","unstructured":"Valz Gris A, Vicente AM, Boccia S. Implementation of genetic tests for disease prevention: challenges in evidence synthesis across clinical utility domains. Eur J Public Health. 2025;35:399\u2013400.","journal-title":"Eur J Public Health"},{"key":"2131_CR42","unstructured":"Jansen M, Onstwedder S, van der Bel R, Njio A, Weda M, Rigter T, et al. DNA technology for the Dutch population. Field consultation for a DNA strategy and policy plan for the Ministry of Health, Welfare and Sport. 2023. Available from: https:\/\/www.rivm.nl\/publicaties\/dna-technologie-voor-nederlandse-bevolking-veldconsultatie-voor-dna-visie. [Accessed in October 2025]."},{"key":"2131_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1099541","volume":"14","author":"S Shaaban","year":"2023","unstructured":"Shaaban S, Ji Y. Pharmacogenomics and health disparities, are we helping? Front Genet. 2023;14:1099541.","journal-title":"Front Genet"},{"key":"2131_CR44","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2217\/pgs-2023-0179","volume":"24","author":"SA Shue","year":"2023","unstructured":"Shue SA, Rowe E, Bell LA, Damush T, DeLong A, Gowan T, et al. Pharmacogenomics implementation across multiple clinic settings: a qualitative evaluation. Pharmacogenomics. 2023;24:881\u201393.","journal-title":"Pharmacogenomics"},{"key":"2131_CR45","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1089\/omi.2016.0122","volume":"20","author":"M Alessandrini","year":"2016","unstructured":"Alessandrini M, Chaudhry M, Dodgen TM, Pepper MS. Pharmacogenomics and global precision medicine in the context of adverse drug reactions: top 10 opportunities and challenges for the next decade. Omics. 2016;20:593\u2013603.","journal-title":"Omics"},{"key":"2131_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2025.101529","volume":"27","author":"CJ Klein","year":"2025","unstructured":"Klein CJ, Gong L, Caudle KE, Naik H, Empey PE, Hoffman JM, et al. Toward an integrated resource for pharmacogenomics (PGx): Survey findings from the genomic medicine communities. Genet Med. 2025;27:101529.","journal-title":"Genet Med"},{"key":"2131_CR47","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/healthcare10091629","volume":"10","author":"D Horgan","year":"2022","unstructured":"Horgan D, Hajduch M, Vrana M, Soderberg J, Hughes N, Omar MI, et al. European Health Data Space\u2014an opportunity now to grasp the future of data-driven healthcare. Healthcare. 2022;10:1629.","journal-title":"Healthcare"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02131-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02131-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02131-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:59:34Z","timestamp":1779965974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-026-02131-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":47,"alternative-id":["2131"],"URL":"https:\/\/doi.org\/10.1038\/s41431-026-02131-9","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Medical Ethics Review Committee of Amsterdam University Medical Centers evaluated the study design and decided that the Medical Research Involving Medical Subjects Act (WMO) does not apply to this study and that further official approval was not required (2024.0141). As the study involved an expert workshop, the experts were informed via email and an information handout (Supplementary Material 2) that the session would be recorded and transcribed. Consent was obtained to record the workshop for the preparation of a report for the EU as Deliverable for the PROPHET project, and all transcripts were anonymized prior to analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}